The Global Health Body Issues Concern Over Severe Lack of Weight-Loss Injections
Fewer than one in 10 patients who could benefit from obesity jabs like Wegovy can access them, states the global health agency as it issues its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for broader and more equitable access to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be managed with thorough and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant hurdles to broad access to the jabs that can help people shift significant weight, says the agency.
Skinny Jab Supply Crisis
Even under the present most optimistic case, the supply of GLP-1 therapies might only reach around 100 million people – under 10% of eligible patients, according to the health organization.
The advice encourages nations and manufacturers to widen availability, by measures including voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Obesity Jabs Operate
GLP-1 drugs mimick a body's own hormone to slow digestion, suppress the appetite and increase the sense of being full so people consume fewer calories.
Patients typically begin shedding pounds after several weeks of beginning the regular doses.
Studies indicates patients may see weight return after a year of stopping the treatment, when their typical hunger return.
Being carrying excess weight increases your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects people in every country and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
